As part of your daily routine as an active trader or investor, it's important to track the stocks in the market that are making the biggest percentage gains and the biggest percentage losses.

Stocks that are making large moves to the upside are favorites among short-term traders who want to capture some of that massive volatility. Stocks that are making big-percentage moves are usually in play because their sector is becoming attractive or they have a major fundamental catalyst such as a recent earnings release. Sometimes stocks making big moves have been hit with an analyst upgrade or an analyst downgrade.

Stocks that are in favor and making large moves is a segment of the market that I tweet about on a regular basis.These are also the exact type of stocks that I love to trade and alert in real-time.

Regardless of the reason behind it, when a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits. If you time your trade correctly, combining with fundamental trends, discipline and sound money management, you will be well on your way to investment success.

With that in mind, let's take a closer look at a several stocks under $10 that are making large moves to the upside.

Ardelyx

  • Thursday's Range: $7.41-$8.02
  • 52-Week Range: $6.84-$22.48
  • Thursday's Volume: 312,000
  • Three-Month Average Volume: 301,311

Ardelyx  (ARDX - Get Report)  discovers, develops and commercializes minimally systemic therapeutics for the gastrointestinal tract to treat GI and cardio-renal diseases. This stock closed up 3% to $7.77 in Thursday's trading session.

From a technical perspective, Ardelyx trended notably higher on Thursday with slightly above-average volume. This move is now quickly pushing this stock within range of triggering a big breakout trade above some key near-term overhead resistance levels. That trade will trigger if shares of Ardelyx manage to clear some near-term overhead resistance levels at its 20-day moving average of $7.96 a share and then above more key resistance levels at $8.10 to $8.26 a share with high volume.

Traders should now look for long-biased trades in Ardelyx long as it's trending above some recent double bottom support levels at $6.84 to $6.88 a share and then once it sustains a move or close above those breakout levels with volume that hits near or above 301,311 shares. If that breakout hits soon, then this stock will set up to re-test or possibly take out its next major overhead resistance levels at $8.88 to its 50-day moving average of $9.37, or even around $10 a share.

BioCryst Pharmaceuticals

  • Thursday's Range: $2.73-$2.89
  • 52-Week Range: $1.63-$16.83
  • Thursday's Volume: 1.54 million
  • Three-Month Average Volume: 1.53 million

BioCryst Pharmaceuticals  (BCRX - Get Report) , a biotechnology company, designs, optimizes and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. This stock traded up 3.2% to $2.83 in Thursday's trading session.

From a technical perspective, BioCryst Pharmaceuticals trended notably higher on Thursday right off its 20-day moving average of $2.72 a share with decent upside volume flows. This stock has been making mostly higher lows and higher highs, over the last few weeks, which is bullish technical price action. This jump to the upside on Thursday is now quickly pushing shares of BioCryst Pharmaceuticals within range of triggering a big breakout trade. That trade will trigger if this stock manages to take out some near-term overhead resistance levels at $2.89 to $2.97 a share with high volume.

Traders should now look for long-biased trades in BioCryst Pharmaceuticals s as long as it's trending above some key near-term support levels at $2.48 or at $2.36 a share and then once it sustains a move or close above those breakout levels with volume that hits near or above 1.53 million shares. If that breakout fires off soon, then this stock will set up to re-test or possibly take out its next major overhead resistance level at $3.24 a share. Any high-volume move above $3.24 will then give this stock a chance to re-fill some of its previous gap-down-day zone from February that started near $7 a share.


Affimed

  • Thursday's Range: $3.58-$3.94
  • 52-Week Range: $2.76-$24.20
  • Thursday's Volume: 306,000
  • Three-Month Average Volume: 332,610

Affimed  (AFMD - Get Report) , a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies. This stock traded up 1.3% to $3.74 in Thursday's trading session.

From a technical perspective, Affimed trended notably higher on Thursday right off its 50-day moving average of $3.55 a share and briefly back above its 20-day moving average of $3.88 a share with decent upside volume flows. This stock recently formed a double bottom chart pattern, after shares found some buying interest at $3.50 to $3.40 a share. Following that potential bottom, shares of Affimed have now started to spike higher and move within range of triggering a big breakout trade. That trade will trigger if this stock manages to take out some near-term overhead resistance levels at $3.95 to $4.18 a share and then above more resistance at $4.23 a share with high volume.

Traders should now look for long-biased trades in Affimed as long as it's trending above those recent double bottom support levels and then once it sustains a move or close above those breakout levels with volume that hits near or above 332,610 shares. If that breakout takes hold soon, then this stock will set up to re-test or possibly take out its next major overhead resistance levels at $4.50 to $4.63, or even $5.10 a share.

Adaptimmune Therapeutics

  • Thursday's Range: $7.81-$8.24
  • 52-Week Range: $6.19-$21.57
  • Thursday's Volume: 274,000
  • Three-Month Average Volume: 290,362

Adaptimmune Therapeutics  (ADAP - Get Report) , a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its T-cell receptor platform. This stock traded up 5% to $8.13 in Thursday's trading session.

From a technical perspective, Adaptimmune Therapeutics jumped sharply higher on Thursday right off its 50-day moving average of $7.88 a share and back above its 20-day moving average of $8.07 a share with decent upside volume flows. This stock recently formed a major bottoming chart pattern, after shares found some buying interest at $7.55, $7.41 and $7.45 a share. Following that potential bottom, shares of Adaptimmune have now started to spike higher and it's quickly moving within range of triggering a big breakout trade. That trade will trigger if this stock manages to take out some near-term overhead resistance levels at Thursday's intraday high of $8.24 a share and then above more key resistance levels at $8.49 to $8.61 a share with high volume.

Traders should now look for long-biased trades in Adaptimmune Therapeutics as long as it's trending above some key near-term support levels at $7.45 to $7.41 a share and then once it sustains a move or close above those breakout levels with volume that hits near or above 274,836 shares. If that breakout materializes soon, then this stock will set up to re-test or possibly take out is next major overhead resistance levels at $9 to $9.73, or even $10 to $10.50 a share.

 

Sangamo Biosciences

  • Thursday's Range: $5.72-$6.23
  • 52-Week Range: $4.63-$16.10
  • Thursday's Volume: 1.24 million
  • Three-Month Average Volume: 1.08 million

Sangamo Biosciences  (SGMO - Get Report) , a clinical stage biopharmaceutical company, focuses on the research, development and commercialization of engineered DNA-binding proteins for therapeutic genome editing and gene regulation. This stock traded up 5.4% to $6.05 in Thursday's trading session.

From a technical perspective, Sangamo Biosciences ripped sharply higher on Thursday right off both its 50-day moving average of $5.74 a share and its 20-day moving average of $5.75 a share with strong upside volume flows. This high-volume spike managed to push this stock into breakout territory, after it closed above some near-term resistance at $6.02 a share. Shares of Sangamo Biosciences are now quickly trending within range of triggering another big breakout trade above some key near-term overhead resistance levels. That trade will trigger if this stock manages to take out some near-term overhead resistance levels at $6.23 to $6.25 a share with high volume.

Traders should now look for long-biased trades in Sangamo Biosciences as long as it's trending above its 50-day moving average at $5.75 a share or above more near-term support at $5.50 a share and then once it sustains a move or close above those breakout levels with volume that registers near or above 1.08 million shares. If that breakout hits soon, then this stock will set up to re-test or possibly take out its next major overhead resistance levels at $6.68 to $6.95, or even its 200-day moving average of $7.54 to $7.75 a share.

Disclosure: This article is commentary by an independent contributor. At the time of publication, the author held no positions in the stocks mentioned.